AEON Biopharma Reports Inducement Grants Under NYSE American LLC Company Guide Section 711
Rhea-AI Summary
AEON Biopharma (NYSE: AEON) has announced the approval of inducement awards in connection with Rob Bancroft's appointment as President and Chief Executive Officer. The Company's Compensation Committee has approved two key grants:
1. A non-qualified stock option to purchase 59,034 shares of AEON Class A common stock, with an exercise price matching the closing price on the grant date
2. 177,103 restricted stock units (RSUs) to be granted upon Form S-8 registration filing or employment start date
Both awards will vest over a four-year period, with 25% vesting annually from the employment start date. These grants are being made under AEON's 2025 Employment Inducement Incentive Award Plan and comply with Section 711 of NYSE American Company Guide.
Positive
- Successful recruitment of new President and CEO indicating strategic leadership transition
- Structured compensation package aligning executive interests with long-term shareholder value
Negative
- Potential shareholder dilution from new equity grants
News Market Reaction – AEON
In the trading session that priced this news, AEON gained 1.25%, reflecting a mild positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
AI-generated analysis. How Rhea-AI works. Not financial advice.
IRVINE, Calif., April 21, 2025 (GLOBE NEWSWIRE) -- AEON Biopharma, Inc. (“AEON” or the “Company”) (NYSE: AEON), a clinical-stage biopharmaceutical company focused on developing a botulinum toxin complex for the treatment of multiple therapeutic indications, today announced that, in connection with the appointment of Rob Bancroft as President and Chief Executive Officer, the Company’s Compensation Committee of the Board of Directors has approved the grant of inducement awards.
The Compensation Committee approved the grant to Mr. Bancroft of a non-qualified stock option to purchase 59,034 shares of AEON Class A common stock under AEON’s 2025 Employment Inducement Incentive Award Plan (the “Inducement Plan”), which provides for the granting of equity awards to new employees of the Company. The stock option will be granted on Mr. Bancroft’s employment start date and will have an exercise price equal to the closing price of AEON’s Class A common stock on the NYSE American on the grant date. In addition, the Compensation Committee approved the grant to Mr. Bancroft of 177,103 restricted stock units (“RSUs”) under the Inducement Plan. The RSUs will be granted on the later of (i) the date on which the Company files a Form S-8 registration statement with respect to the Inducement Plan and (ii) Mr. Bancroft’s employment start date.
The stock option and RSUs vest over four years,
About AEON Biopharma
AEON is a clinical stage biopharmaceutical company focused on developing its proprietary botulinum toxin complex, ABP-450 (prabotulinumtoxinA) injection, or ABP-450, for debilitating medical conditions, with an initial focus on the neurosciences market. ABP-450 is the same botulinum toxin complex that is currently approved and marketed for cosmetic indications by Evolus under the name Jeuveau. ABP-450 is manufactured by Daewoong in compliance with current Good Manufacturing Practice, or cGMP, in a facility that has been approved by the U.S. Food and Drug Administration, Health Canada and European Medicines Agency. The product is approved as a biosimilar in Mexico and India. AEON has exclusive development and distribution rights for therapeutic indications of ABP-450 in the United States, Canada, the European Union, the United Kingdom, and certain other international territories. The Company has built a highly experienced management team with specific experience in biopharmaceutical and botulinum toxin development and commercialization. To learn more about AEON, visit www.aeonbiopharma.com.
Contacts
Investor Contact:
Corey Davis, Ph.D.
LifeSci Advisors
+1 212 915 2577
cdavis@lifesciadvisors.com
Source: AEON Biopharma
